Andrew Burke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrew Burke has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Rachel Thomson
Greenslopes Clinical Unit, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Greenslopes, Australia
2 shared publications Adam Stewart
Central Microbiology Laboratory Pathology Queensland Brisbane Australia
1 shared publication- Ai Ling Tan
Pleural Medicine Unit, Institute for Respiratory Health, Nedlands, Perth, WA 6009, Australia
1 shared publication Alex Chadwick
The Prince Charles Hospital, Brisbane, Queensland, Australia
1 shared publicationAlex Chaudhuri
Infectious Diseases Department The Prince Charles Hospital Brisbane Queensland Australia
1 shared publicationAlice Sawka
Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia; University of Adelaide, Adelaide, South Australia, Australia
1 shared publication
Latest Publications
- Open Access
- 17 September 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70315
Invasive Fungal Infections in Heart Transplants: A 10‐Year, Single Centre Retrospective Cohort Study From Subtropical Australia
Background: Invasive fungal infections (IFIs) are a major cause of morbidity and mortality in solid organ transplant recipients. However, their epidemiology in Australian heart transplant cohorts remains poorly defined. We aimed to determine the incidence, microbiological profile, diagnostic performance, and survival outcomes associated with IFIs in heart transplant recipients. Methods: We conducted a retrospective cohort study of all heart transplant patients who were diagnosed with an IFI between January 1, 2014 and February 29, 2024 at a single center in Queensland, Australia. Patient characteristics, details of transplant hospitalization, antifungal prophylaxis, microbiology, and treatment of fungal infections were described. Results: Of 73 patients with suspected IFI, 48 met criteria for possible 19% ( n = 9), probable 27% ( n = 13), or proven 54% ( n = 26) infection. Aspergillus 33% ( n = 16), Candida 17% ( n = 8), Scedosporium 13% ( n = 6), and polymicrobial infections 8% ( n = 4) were most common. Median time to IFI diagnosis was 7 months post‐transplant. Of 148 patients who received heart transplants at the center between January 2014 and February 2024, 32 developed IFI; estimated incidence was 49 (95% CI: 35–70) per 1000 person years. Among those who died ( n = 21), median time from transplant to death was 5.75 years. Baseline Charlson comorbidity index was the only variable significantly associated with all‐cause mortality ( p = 0.041). Conclusion: IFIs in heart transplant recipients frequently occur beyond the first year posttransplant. Higher Charlson scores were associated with reduced survival. These findings support the need for tailored prophylaxis strategies and improved diagnostic algorithms in preventing posttransplant IFI. image
- 17 September 2026
- Published by Wiley in Transplant Infectious Disease
- p. e70315
Open AccessInvasive Fungal Infections in Heart Transplants: A 10‐Year, Single Centre Retrospective Cohort Study From Subtropical Australia
Background: Invasive fungal infections (IFIs) are a major cause of morbidity and mortality in solid organ transplant recipients. However, their epidemiology in Australian heart transplant cohorts remains poorly defined. We aimed to determine the incidence, microbiological profile, diagnostic performance, and survival outcomes associated with IFIs in heart transplant recipients. Methods: We conducted a retrospective cohort study of all heart transplant patients who were diagnosed with an IFI between January 1, 2014 and February 29, 2024 at a single center in Queensland, Australia. Patient characteristics, details of transplant hospitalization, antifungal prophylaxis, microbiology, and treatment of fungal infections were described. Results: Of 73 patients with suspected IFI, 48 met criteria for possible 19% ( n = 9), probable 27% ( n = 13), or proven 54% ( n = 26) infection. Aspergillus 33% ( n = 16), Candida 17% ( n = 8), Scedosporium 13% ( n = 6), and polymicrobial infections 8% ( n = 4) were most common. Median time to IFI diagnosis was 7 months post‐transplant. Of 148 patients who received heart transplants at the center between January 2014 and February 2024, 32 developed IFI; estimated incidence was 49 (95% CI: 35–70) per 1000 person years. Among those who died ( n = 21), median time from transplant to death was 5.75 years. Baseline Charlson comorbidity index was the only variable significantly associated with all‐cause mortality ( p = 0.041). Conclusion: IFIs in heart transplant recipients frequently occur beyond the first year posttransplant. Higher Charlson scores were associated with reduced survival. These findings support the need for tailored prophylaxis strategies and improved diagnostic algorithms in preventing posttransplant IFI. image
- 25 February 2026
- Published by University of Queensland Library
The Pharmacokinetics & Pharmacodynamics of Antimycobacterial Drugs in People with Cystic Fibrosis and Drug-Resistant Tuberculosis Infection
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 25 February 2026
- Published by University of Queensland Library
The Pharmacokinetics & Pharmacodynamics of Antimycobacterial Drugs in People with Cystic Fibrosis and Drug-Resistant Tuberculosis Infection
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- Open Access
- 12 December 2025
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (1)
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
Background and objectives: Mycobacterium abscessus has extensive innate and acquired antibiotic resistance resulting in limited antibiotic treatment options and poor clinical outcomes. Currently, the only β-lactam antibiotics with efficacy against M. abscessus are imipenem and cefoxitin. Durlobactam is a β-lactamase inhibitor that may overcome intrinsic resistance mechanisms and enable the use of alternative oral β-lactam antibiotics. The objective of this study was to determine whether sulbactam/durlobactam increases the susceptibility of M. abscessus to alternative β-lactam antibiotics. Material and methods: Antibiotic susceptibility testing was performed for durlobactam, meropenem, cefuroxime/amoxicillin alone, and sulbactam/durlobactam alone and in combination with meropenem and cefuroxime/amoxicillin according to Clinical Laboratory Standards Institute (CLSI) standards. These results were then compared with imipenem susceptibility with and without relebactam. Results: Sulbactam/durlobactam significantly lowered the MICs of M. abscessus to meropenem, cefuroxime and cefuroxime/amoxicillin to MICs comparable to those of imipenem and imipenem/relebactam. The culture medium used had a significant impact on MIC, with Middlebrook 7H9 having significantly lower MICs for all combinations containing durlobactam compared with CLSI standard CAMHB media. Conclusion: Sulbactam/durlobactam significantly increased susceptibility to oral and intravenous β-lactam antibiotics in the form of cefuroxime, cefuroxime/amoxicillin and meropenem against clinical isolates of M. abscessus. This study also found significant differences in susceptibility to β-lactam antibiotics dependent on the culture media used, highlighting that the optimal culture methods for determining MIC in M. abscessus remains uncertain. Future in vivo studies are required to determine whether the in vitro efficacy of the β-lactam combinations studied could result in clinical efficacy for M. abscessus disease.
- 12 December 2025
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (1)
Open AccessIn vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
Background and objectives: Mycobacterium abscessus has extensive innate and acquired antibiotic resistance resulting in limited antibiotic treatment options and poor clinical outcomes. Currently, the only β-lactam antibiotics with efficacy against M. abscessus are imipenem and cefoxitin. Durlobactam is a β-lactamase inhibitor that may overcome intrinsic resistance mechanisms and enable the use of alternative oral β-lactam antibiotics. The objective of this study was to determine whether sulbactam/durlobactam increases the susceptibility of M. abscessus to alternative β-lactam antibiotics. Material and methods: Antibiotic susceptibility testing was performed for durlobactam, meropenem, cefuroxime/amoxicillin alone, and sulbactam/durlobactam alone and in combination with meropenem and cefuroxime/amoxicillin according to Clinical Laboratory Standards Institute (CLSI) standards. These results were then compared with imipenem susceptibility with and without relebactam. Results: Sulbactam/durlobactam significantly lowered the MICs of M. abscessus to meropenem, cefuroxime and cefuroxime/amoxicillin to MICs comparable to those of imipenem and imipenem/relebactam. The culture medium used had a significant impact on MIC, with Middlebrook 7H9 having significantly lower MICs for all combinations containing durlobactam compared with CLSI standard CAMHB media. Conclusion: Sulbactam/durlobactam significantly increased susceptibility to oral and intravenous β-lactam antibiotics in the form of cefuroxime, cefuroxime/amoxicillin and meropenem against clinical isolates of M. abscessus. This study also found significant differences in susceptibility to β-lactam antibiotics dependent on the culture media used, highlighting that the optimal culture methods for determining MIC in M. abscessus remains uncertain. Future in vivo studies are required to determine whether the in vitro efficacy of the β-lactam combinations studied could result in clinical efficacy for M. abscessus disease.
- Open Access
- 29 April 2025
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (3) , dlaf074
Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy
Background: Tigecycline is increasingly being considered in outpatient parenteral antimicrobial therapy (OPAT) programmes given its spectrum of activity; however, stability data are lacking, necessitating further study. Objective: To assess tigecycline stability in elastomeric infusers under OPAT conditions, following the UK Yellow Cover Document (YCD) stability testing guidelines. Methods: Tigecycline was reconstituted with normal saline in Leventon Dosi-Fuser and Baxter-LV10 infusers at doses of 50, 100 and 200 mg in 240 mL. Additionally, a tigecycline intermittent infusion dose (50 mg/100 mL) was reconstituted in Baxter-SV100 infusers. The infusers were stored under refrigerated storage (2°C–8°C) for 7 days, followed by exposure at an in-use temperature of 32°C for 24 h, or at 25°C for 2 hours for the intermittent infusion. Stability was evaluated using a stability-indicating assay, pH measurement, subvisible particle count and visual inspection as per the YCD. Results: After 7 days of refrigeration followed by 24 h exposure to 32°C, the mean ± SD percentage of tigecycline remaining was 97.9 ± 0.6, 97.3 ± 0.6 and 95.4 ± 0.8 for the Baxter LV10 devices, and 97.2 ± 0.3, 96.9 ± 0.5 and 95.8 ± 0.8 for Dosi-Fuser devices at the low, intermediate, and high dose levels, respectively. For intermittent infusion in Baxter-SV100 devices, the mean ± SD percentage remaining after 7 days of refrigerated storage followed by 2 h at 25°C was 99.7 ± 0.2. Conclusions: Tigecycline meets the UK YCD criteria of ≤5% degradation limit, indicating its suitability for both intermittent and continuous 24-h infusion in OPAT programs.
- 29 April 2025
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (3) , dlaf074
Open AccessEvaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy
Background: Tigecycline is increasingly being considered in outpatient parenteral antimicrobial therapy (OPAT) programmes given its spectrum of activity; however, stability data are lacking, necessitating further study. Objective: To assess tigecycline stability in elastomeric infusers under OPAT conditions, following the UK Yellow Cover Document (YCD) stability testing guidelines. Methods: Tigecycline was reconstituted with normal saline in Leventon Dosi-Fuser and Baxter-LV10 infusers at doses of 50, 100 and 200 mg in 240 mL. Additionally, a tigecycline intermittent infusion dose (50 mg/100 mL) was reconstituted in Baxter-SV100 infusers. The infusers were stored under refrigerated storage (2°C–8°C) for 7 days, followed by exposure at an in-use temperature of 32°C for 24 h, or at 25°C for 2 hours for the intermittent infusion. Stability was evaluated using a stability-indicating assay, pH measurement, subvisible particle count and visual inspection as per the YCD. Results: After 7 days of refrigeration followed by 24 h exposure to 32°C, the mean ± SD percentage of tigecycline remaining was 97.9 ± 0.6, 97.3 ± 0.6 and 95.4 ± 0.8 for the Baxter LV10 devices, and 97.2 ± 0.3, 96.9 ± 0.5 and 95.8 ± 0.8 for Dosi-Fuser devices at the low, intermediate, and high dose levels, respectively. For intermittent infusion in Baxter-SV100 devices, the mean ± SD percentage remaining after 7 days of refrigerated storage followed by 2 h at 25°C was 99.7 ± 0.2. Conclusions: Tigecycline meets the UK YCD criteria of ≤5% degradation limit, indicating its suitability for both intermittent and continuous 24-h infusion in OPAT programs.
- 17 December 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (6) , 1521-1531
Imipenem Pharmacokinetics/Pharmacodynamics in Preclinical Hollow Fiber Model, Dose Finding in Virtual Patients, and Clinical Evidence of Efficacy for Mycobacterium abscessus Lung Disease
Background: Guideline-based therapy (GBT) for Mycobacterium abscessus (Mab) lung disease achieves sputum culture conversion (SCC) rates of 35%. This poor GBT efficacy is mirrored in the hollow fiber system model of Mab (HFS-Mab). While imipenem is part of GBT, its biologic effect, with or without β-lactamase inhibitors, is unproven. Methods: We performed imipenem-relebactam minimum inhibitory concentration (MIC) in 122 Mab isolates, and an exposure-response study in the HFS-Mab using human intrapulmonary pharmacokinetics. The percentage of time that concentration persisted above the MIC (TMIC), mediating maximal effect in the HFS-Mab, was used as the exposure target for dose finding in a Monte Carlo experiment including 10 000 virtual patients. For real-world evidence, we performed a patient, intervention (imipenem), comparison (no β-lactam), and outcome (SCC) (PICO) analysis. Results: Imipenem killed 1.32 log10 colony-forming units/mL below the day 0 level in HFS-Mab. The average target exposure for imipenem was a TMIC of 47.9% (SD, 9.77%). Infusion of 1 g every 6 hours achieved the target in >90% of virtual patients in Monte Carlo experiments. The pharmacokinetic-pharmacodynamic MIC break point was 1 mg/L. In PICO analyses, the median time to SCC was 470 days in comparators, 311 days for imipenem added on to a failing regimen, and 37 days in newly treated patients (P = .049). The odds ratio for SCC when imipenem was part of the initial regimen, versus comparators, was 12.5 (95% confidence interval, 1.47–84.55). No patients receiving imipenem experienced treatment-limiting adverse events, compared with 2 of 7 comparators (P = .046). Middlebrook 7H9 broth MIC distribution, read at 24 hours, was better correlated with patient responses than cation-adjusted Mueller-Hinton broth. Conclusions: Imipenem demonstrated biologic effect in the HFS-Mab and in patients. Imipenem-relebactam doses of 1 g every 6 hours are recommended.
- 17 December 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (6) , 1521-1531
Imipenem Pharmacokinetics/Pharmacodynamics in Preclinical Hollow Fiber Model, Dose Finding in Virtual Patients, and Clinical Evidence of Efficacy for Mycobacterium abscessus Lung Disease
Background: Guideline-based therapy (GBT) for Mycobacterium abscessus (Mab) lung disease achieves sputum culture conversion (SCC) rates of 35%. This poor GBT efficacy is mirrored in the hollow fiber system model of Mab (HFS-Mab). While imipenem is part of GBT, its biologic effect, with or without β-lactamase inhibitors, is unproven. Methods: We performed imipenem-relebactam minimum inhibitory concentration (MIC) in 122 Mab isolates, and an exposure-response study in the HFS-Mab using human intrapulmonary pharmacokinetics. The percentage of time that concentration persisted above the MIC (TMIC), mediating maximal effect in the HFS-Mab, was used as the exposure target for dose finding in a Monte Carlo experiment including 10 000 virtual patients. For real-world evidence, we performed a patient, intervention (imipenem), comparison (no β-lactam), and outcome (SCC) (PICO) analysis. Results: Imipenem killed 1.32 log10 colony-forming units/mL below the day 0 level in HFS-Mab. The average target exposure for imipenem was a TMIC of 47.9% (SD, 9.77%). Infusion of 1 g every 6 hours achieved the target in >90% of virtual patients in Monte Carlo experiments. The pharmacokinetic-pharmacodynamic MIC break point was 1 mg/L. In PICO analyses, the median time to SCC was 470 days in comparators, 311 days for imipenem added on to a failing regimen, and 37 days in newly treated patients (P = .049). The odds ratio for SCC when imipenem was part of the initial regimen, versus comparators, was 12.5 (95% confidence interval, 1.47–84.55). No patients receiving imipenem experienced treatment-limiting adverse events, compared with 2 of 7 comparators (P = .046). Middlebrook 7H9 broth MIC distribution, read at 24 hours, was better correlated with patient responses than cation-adjusted Mueller-Hinton broth. Conclusions: Imipenem demonstrated biologic effect in the HFS-Mab and in patients. Imipenem-relebactam doses of 1 g every 6 hours are recommended.
- Open Access
- 17 June 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 818
New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?
Multidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity. As such, it is imperative to identify novel alternatives that are better tolerated but equally or more effective. Therefore, this review aims to identify and explore the novel alternative oxazolidinones to potentially replace linezolid in the management of TB. The keywords tuberculosis and oxazolidinones were searched in PubMed to identify eligible compounds. The individual drug compounds were then searched with the term tuberculosis to identify the relevant in vitro, in vivo and clinical studies. The search identified sutezolid, tedizolid, delpazolid, eperezolid, radezolid, contezolid, posizolid and TBI-223, in addition to linezolid. An additional search resulted in 32 preclinical and 21 clinical studies. All novel oxazolidinones except posizolid and eperezolid resulted in positive preclinical outcomes. Sutezolid and delpazolid completed early phase 2 clinical studies with better safety and equal or superior efficacy. Linezolid is expected to continue as the mainstay therapy, with renewed interest in drug monitoring. Sutezolid, tedizolid, delpazolid and TBI-223 displayed promising preliminary results. Further clinical studies would be required to assess the safety profiles and optimize the dosing regimens.
- 17 June 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 818
Open AccessNew Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?
Multidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity. As such, it is imperative to identify novel alternatives that are better tolerated but equally or more effective. Therefore, this review aims to identify and explore the novel alternative oxazolidinones to potentially replace linezolid in the management of TB. The keywords tuberculosis and oxazolidinones were searched in PubMed to identify eligible compounds. The individual drug compounds were then searched with the term tuberculosis to identify the relevant in vitro, in vivo and clinical studies. The search identified sutezolid, tedizolid, delpazolid, eperezolid, radezolid, contezolid, posizolid and TBI-223, in addition to linezolid. An additional search resulted in 32 preclinical and 21 clinical studies. All novel oxazolidinones except posizolid and eperezolid resulted in positive preclinical outcomes. Sutezolid and delpazolid completed early phase 2 clinical studies with better safety and equal or superior efficacy. Linezolid is expected to continue as the mainstay therapy, with renewed interest in drug monitoring. Sutezolid, tedizolid, delpazolid and TBI-223 displayed promising preliminary results. Further clinical studies would be required to assess the safety profiles and optimize the dosing regimens.
- 14 August 2023
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 44 (4) , 815-828
Medications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease
- 14 August 2023
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 44 (4) , 815-828
Medications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease
- Open Access
- 28 July 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 62 (4) , 106938
In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates
- 28 July 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 62 (4) , 106938
Open AccessIn vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates
- 27 March 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (3) , e14058
Mycoplasma hominis and Ureaplasma urealyticum infections in the immediate post‐lung transplant period: A case series and literature review
Mycoplasma hominis and Ureaplasma species infections in the post‐transplant setting are believed to be donor‐derived and can be associated with poor outcomes. Difficulty in culturing and identifying these organisms is a significant barrier to diagnosis and early intervention. Tetracyclines, macrolides and fluoroquinolones are the mainstay treatments to cure these infections; however, there are increasing reports of antibiotic resistance. In this case series, we report our single‐centre experience with M. hominis and U. urealyticum infection after lung transplantation (9 recipients, all men, mean age 56 years). Delayed diagnosis was common. Young donor age (mean age 23 yrs) and high‐risk donor social history (67%) were repeatedly noted in these cases, and all infections were associated with significant morbidity (anastomosis and sternal wound infection, empyema, mediastinitis, pericarditis). Two patients died; with one directly related to Ureaplasma urealyticum infection. In conclusion post lung transplant M. hominis, and U. urealyticum infections are challenging and carry high morbidity. More prospective studies are required to assess the true prevalence, full spectrum of complications and utility of molecular diagnostics to aid early diagnosis and identify antibiotic susceptibility of Mycoplasma and Ureaplasma infections in the post‐lung transplant setting. image
- 27 March 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (3) , e14058
Mycoplasma hominis and Ureaplasma urealyticum infections in the immediate post‐lung transplant period: A case series and literature review
Mycoplasma hominis and Ureaplasma species infections in the post‐transplant setting are believed to be donor‐derived and can be associated with poor outcomes. Difficulty in culturing and identifying these organisms is a significant barrier to diagnosis and early intervention. Tetracyclines, macrolides and fluoroquinolones are the mainstay treatments to cure these infections; however, there are increasing reports of antibiotic resistance. In this case series, we report our single‐centre experience with M. hominis and U. urealyticum infection after lung transplantation (9 recipients, all men, mean age 56 years). Delayed diagnosis was common. Young donor age (mean age 23 yrs) and high‐risk donor social history (67%) were repeatedly noted in these cases, and all infections were associated with significant morbidity (anastomosis and sternal wound infection, empyema, mediastinitis, pericarditis). Two patients died; with one directly related to Ureaplasma urealyticum infection. In conclusion post lung transplant M. hominis, and U. urealyticum infections are challenging and carry high morbidity. More prospective studies are required to assess the true prevalence, full spectrum of complications and utility of molecular diagnostics to aid early diagnosis and identify antibiotic susceptibility of Mycoplasma and Ureaplasma infections in the post‐lung transplant setting. image